ikk inhibitor bay  (MedChemExpress)

Journal: Clinical and Translational Medicine

Article Title: Single‐cell landscape of the tumour immune microenvironment in human gynaecologic malignancies

doi: 10.1002/ctm2.70538

Figure Lengend Snippet: Validation of the regulatory function of NFKB1 and the prognostic relevance of IFN‐Mac_CXCL9 and Angio‐Mac. (A and B) Bar plots showing VEGFA secretion and expression in THP‐1 derived M2 macrophages after NFKB1 knockout (A) or treatment with an IKK inhibitor–BAY 11‐7082 (B). (C‐D) Representative images of mIHC staining for IFN‐Mac_CXCL9 (C) using CD68, CXCL9 and PITX1 and Angio‐Mac (D) using CD68, VCAN and NFKB1. The arrows indicate cells positive for all three markers. Scale bars, 100 µm.

Article Snippet: M2 macrophages were derived from M0 cells via IL‐4 (20 ng/mL, 200‐04; Sigma–Aldrich) and IL‐13 (20 ng/mL, 200‐13; PeproTech) treatment for 48 h, followed by treatment with the IKK inhibitor BAY 11‐7082 (20 μM, HY‐13453, MCE) for another 48 h. VEGFA levels in the culture supernatants were measured via ELISA (ABclonal RK00023), and total RNA was extracted for qPCR analysis.

Techniques: Biomarker Discovery, Expressing, Derivative Assay, Knock-Out, Staining

Journal: Nature cancer

Article Title: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2.

doi: 10.1038/s43018-023-00712-x

Figure Lengend Snippet: Fig. 1 | PD-L2 is upregulated in human and murine cancer cell lines on induction of cellular senescence. a,b, Representative images of SA-β-gal staining (a, scale bar, 50 μm) and PD-L1 and PD-L2 mRNA expression in human cancer cell lines treated with palbociclib (b, n = 3 experiments). c, PD-L1 and PD- L2 mRNA expression in murine cancer cell lines after treatment with doxorubicin (n = 3 experiments). d, PD-L1 and PD-L2 mRNA expression in SK-MEL-103 xenograft tumors in nude mice, treated with 100 mg kg−1 oral palbociclib for 10 days and euthanized after the treatment. Control (n = 6 tumors); palbociclib- treated tumors (n = 7). e, PD-L1 and PD-L2 mRNA expression in HCmel3 tumors in C57BL/6 mice treated with 5 mg kg−1 doxorubicin (days 7, 10 and 17), analyzed after day 19. Control (n = 3 tumors); doxorubicin-treated tumors (n = 6). f, PD-L1 and PD-L2 mRNA expression in SK-MEL-28 cells treated with doxorubicin and then with the IKK inhibitor BAY 11-7082 (3 μM, 24 h, n = 3 experiments). g, PD-L1 and PD-L2 mRNA expression in SK-MEL-28 cells treated with TNF-α (100 ng ml−1, 3 days, n = 3 experiments). h, Quantification of PD-L2 protein levels using flow

Article Snippet: For IKK inhibition, cells were treated at day 6 with either vehicle (dimethylsulfoxide) or the IKK inhibitor BAY 11-7082 (Selleck Chemicals) at 3 μM for 24 h. Human TNF-α recombinant protein (Thermo Fisher Scientific) was used at 100 ng ml−1 for 3 days.

Techniques: Staining, Expressing, Control

Journal: Marine Drugs

Article Title: Anti-Inflammatory Azaphilones from the Edible Alga-Derived Fungus Penicillium sclerotiorum

doi: 10.3390/md19100529

Figure Lengend Snippet: Effects of compounds on NFκB signaling and activity. 20 ng/mL TNF-α together with or without 20 μM of the individual compound were treated to TPH cells for 30 min ( A , B ; n = 3) or to the NFκB reporter cells for 24 h ( C ; n = 6). 10 μM IκB/IKK inhibitor BAY 11-7082 serve as a positive control. * for p < 0.05, ** for p < 0.01, and *** for p < 0.001.

Article Snippet: IκB/IKK inhibitor BAY 11-7082 (Cayman) and TGFβRI inhibitor LY3200882 (Medchemexpres) as positive controls.

Techniques: Activity Assay, Positive Control